February was a challenging month for health and biotech stocks, but it did make a modest gain of 1.86 percent on the month of January. 

Of 133 health and biotech ASX small cap stocks, 83 have lost ground whilst 42 have gained and 8 stagnated.

As with any large portfolio of shares some stocks significantly outperformed their peers.

In this sector clinical studies can make or break stocks and this month’s performance was proof of that.

Who were this month’s winners

Bionomics (ASX: BNO) was the biggest winner this month, doubling after positive clinical trial results.

Its anti-post traumatic stress disorder (PTSD) drug showed positive results when exposure was adequate.

While shareholders will have to wait a few months for the full data set, the results were enough to send the company higher.

A company that was victim of a failed trial, Factor Therapeutics (ASX: FTT), was actually the second biggest gainer.

After plummeting 95 percent back in November, some might declare its modest rise from its 0.002 cent low a dead cat bounce. But now there is speculation the future is brighter with a board overhaul looming.

While a meeting will not occur until late March the board told shareholders it has identified a “high-potential biotechnology asset opportunity and negotiations are now at the point of detailed due diligence, a process for which the current Board is extremely well-suited.”

The third was Althea Group Holdings (ASX: AGH) who announced expansion into the UK medical cannabis market.

This month, Althea have also announced a product supply and distribution agreement with Cannvalate.

Cannvalate has a network of over 1,000 doctors and 600 pharmacies and investors received the partnership well.

Top 20 performing health and biotech small cap ASX stocks

Ticker Name Market Cap Price (28-Feb) Total Return February (%) Total Return

YTD (%)

BNO BIONOMICS LTD $ 130,724,608.00 0.23 100 128.5714
FTT FACTOR THERAPEUTICS LTD $ 4,171,342.50 0.004 60 100
AGH ALTHEA GROUP HOLDINGS LTD $ 86,406,752.00 0.41 44.0678 73.4694
HMD HERAMED LTD $ 20,613,692.00 0.235 34.2857 46.875
IPD IMPEDIMED LTD $ 94,826,080.00 0.255 31.5789 31.5789
BLT BENITEC BIOPHARMA LTD $ 33,413,826.00 0.135 26.8293 23.8095
SDI SDI LTD $ 99,252,720.00 0.85 26.5151 27.4809
GSS GENETIC SIGNATURES LTD $ 94,664,512.00 0.91 21.3333 13.75
NSB NEUROSCIENTIFIC BIOPHARMACEUTICALS $ 14,716,118.00 0.2 21.2121 53.8462
BOT BOTANIX PHARMACEUTICALS LTD $ 83,767,712.00 0.115 20.8791 57.1429
AXP AIRXPANDERS INC-CDI $ 21,221,474.00 0.038 18.75 46.1538
NVL NATIONAL VETERINARY CARE LTD $ 137,352,800.00 2.06 17.8161 5.1282
OIL OPTISCAN IMAGING LTD $ 22,499,298.00 0.052 15.5556 15.5556
1ST 1ST GROUP LTD $ 7,843,609.00 0.03 15.3846 3.4483
CYP CYNATA THERAPEUTICS LTD $ 160,869,664.00 1.565 14.4404 21.9231
PBT PRANA BIOTECHNOLOGY LTD $ 22,187,074.00 0.039 14.2857 21.2121
TTB TOTAL BRAIN LTD $ 13,812,757.00 0.026 13.0435 -21.2121
ADO ANTEO DIAGNOSTICS LTD $ 22,035,374.00 0.02 11.7647 11.7647
PCK PAINCHEK LTD $ 32,677,498.00 0.039 11.4286 0

 

Recent and Upcoming entrants

While there have not been any new small cap biotech stock entrants to the ASX this year, this is set to change in March. Cell therapy manufacturer Koligo Therapeutics is set to list towards the end of the month, with the offer closing in two weeks time.

 

This content does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.